The ADEPT trial met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for Dupixent to treat adults with bullous pemphigoid.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

The sBLA is supported by data from a pivotal trial evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP. The primary endpoint was met, with five times more ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo ...